{
    "clinical_study": {
        "@rank": "58550", 
        "arm_group": [
            {
                "arm_group_label": "insulin aspart", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "human insulin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to evaluate the safety profile\n      of insulin aspart in subjects with type 1 diabetes having participated in trial ANA/DCD/035."
        }, 
        "brief_title": "Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "May 2000", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The subject must have completed the six month controlled treatment period in trial\n             ANA/DCD/035"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "753", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01707134", 
            "org_study_id": "ANA/DCD/050"
        }, 
        "intervention": [
            {
                "arm_group_label": "insulin aspart", 
                "description": "Injected subcutaneously (s.c, under the skin) as meal time insulin", 
                "intervention_name": "insulin aspart", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "human insulin", 
                "description": "Injected subcutaneously (s.c, under the skin) as meal time insulin", 
                "intervention_name": "human soluble insulin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "insulin aspart", 
                    "human insulin"
                ], 
                "description": "Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin", 
                "intervention_name": "insulin NPH", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin aspart", 
                "Insulin", 
                "Insulin, NPH"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 17, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "1090"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f8benhavn", 
                        "country": "Denmark", 
                        "zip": "2400"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kotka", 
                        "country": "Finland", 
                        "zip": "48210"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Giessen", 
                        "country": "Germany", 
                        "zip": "35385"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haugesund", 
                        "country": "Norway", 
                        "zip": "5500"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Falun", 
                        "country": "Sweden", 
                        "zip": "791 82"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Z\u00fcrich", 
                        "country": "Switzerland", 
                        "zip": "8032"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom", 
                        "zip": "NG7  2UH"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Denmark", 
                "Finland", 
                "Germany", 
                "Norway", 
                "Sweden", 
                "Switzerland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-labelled, Controlled, Multicentre, Multinational, Extension Study Assessing Safety and Efficacy of the Human Insulin Analogue Insulin Aspart (X14) and Human Soluble Insulin as Meal Related Insulin in a Multiple Injection Regimen in Type 1 Diabetic Subjects", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Hans Henrik Friberg", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Austria: Agency for Health and Food Safety", 
                "Denmark: Danish Medicines Agency", 
                "Finland: Finnish Medicines Agency", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Norway: Norwegian Medicines Agency", 
                "Sweden: Medical Products Agency", 
                "Switzerland: Federal Office of Public Health", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2000", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of hypoglycaemic events", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01707134"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "Occurrence of adverse events", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Incidence of hypoglycaemic episodes", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Standard safety parameters: Haematology and biochemistry", 
                "safety_issue": "No"
            }, 
            {
                "measure": "HbA1c (glycosylated haemoglobin)", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 1997", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}